obesity
Image Gallery
Obesity is associated with many adverse health effects, including an increased risk of diabetes and heart disease.
The combined condition of obesity, diabetes and heart disease is sometimes referred to as the metabolic syndrome.
One of the factors that best correlates obesity with the rest of the metabolic syndrome is not overall body mass, but the distribution of adipose tissue in the abdominal region, visceral obesity.
Glucocorticoids have been associated as a risk factor for the metabolic syndrome, but most obese individuals have normal levels of circulating corticosteroids.
Active corticosteroids such as cortisol and corticosterone activate the glucocorticoid receptor, a nuclear hormone receptor and transcription factor.
Obese individuals have elevated levels in adipose tissue of a key enzyme in glucocorticoid metabolism, 11beta hydroxysteroid dehydrogenase type 1 (11betaHSD-1). 11betaHSD-1 interconverts inactive corticosteroids and the active form.
When present in cells, 11betaHSD-1 can convert inactive corticosteroids from the blood to create locally high concentrations in a tissue such as adipose tissue.
When activated in adipose tissue, GR increases the level of visceral fat, induces insulin resistance and dyslipidemias that increase the risk of heart disease.
The mechanisms by which GR might induce the various aspects of the metabolic syndrome are a key area of research. One of the genes activated by GR is lipoprotein lipase.
When GR is activated in visceral adipose tissue, it will increase the expression of lipoprotein lipase (LPL). This enzyme hydrolyzes triglycerides in plasma, releasing free fatty acids into tissues, where they can be reassembled into triglycerides.
In visceral adipose, this GR-driven overexpression of lipoprotein lipase will result in the increased deposits of visceral fat that are observed. Genes thought to be involved in insulin resistance also appear to be affected by altered 11betaHSD-1 corticosteroid metabolism in visceral fat.
This includes downregulation of resistin and adipoQ, and induction of TNF-alpha. The elevated free fatty acids and active corticosteroids released from visceral fat may account for the metabolic changes in liver associated with the metabolic syndrome.
Antidiabetic thiazoidinedione drugs such as troglitazone and Avandia act as agonists of another nuclear receptor, PPAR-gamma. These drugs activate PPAR-gamma and repress expression of 11betaHSD-1 in visceral tissue, perhaps accounting in part for the antidiabetic insulin sensitizing properties of these drugs.
Predisposition loci
10p12
12q24
13q32
See also
References
Walsh SW. Obesity: a risk factor for preeclampsia. Trends Endocrinol Metab. 2007 Dec;18(10):365-70. PMID: 18023357
Popkin BM. Understanding global nutrition dynamics as a step towards controlling cancer incidence. Nat Rev Cancer. 2007 Jan;7(1):61-7. PMID: 17186019
Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005 Mar;6(3):221-34. PMID: 15703762
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004 Apr;10(4):355-61. PMID: 15057233
Lin SC, Li P. CIDE-A, a novel link between brown adipose tissue and obesity. Trends Mol Med. 2004 Sep;10(9):434-9. PMID: 15350895
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004 Aug;4(8):579-91. PMID: 15286738
Liu YJ, Araujo S, Recker RR, Deng HW. Molecular and genetic mechanisms of obesity: implications for future management. Curr Mol Med. 2003 Jun;3(4):325-40. PMID: 12776988
Camp HS, Ren D, Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med. 2002 Sep;8(9):442-7. PMID: 12223316
Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002 Feb 21;346(8):591-602. PMID: 11856799
Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance—the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2001 Nov 1;345(18):1345-6. PMID: 11794158